MedCity News April 10, 2025
Alzheon hoped testing its drug in a genetically defined subgroup of Alzheimer’s disease patients would succeed, overcoming earlier clinical trial failures. Instead, preliminary results show the pill failed to outdistance a placebo.
An experimental Alzheimer’s disease therapy designed by Alzheon to reduce depositions of amyloid plaque in the brain failed to beat a placebo in a Phase 3 study, the latest blow to a drug whose history is marked by clinical trial shortfalls.
The twice-daily pill, valiltramiprosate, did not meet the main clinical trial goal of slowing cognitive decline measured at 78 weeks, Alzheon announced Thursday. Nevertheless, the Framingham, Massachusetts-based company pointed to measures of brain volume showing a slowing of brain atrophy, which it said suggest potential neuroprotective benefits...
Today's Sponsors
Today's Sponsor